drugset
drugset / Trial / NCT07218783

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)

NCT07218783 ↗

Phase 3 Recruiting 400 enrolled SpyGlass Pharma, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.

Timeline

Start
2025-10-15
Primary completion
2029-03-31
Completion
2031-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimatoprost Other / unclassified 78 ug —
Comparator Timolol Other / unclassified 0.5 % Other

Indications

cataract ocular hypertension open-angle glaucoma